# A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

> **NCT03545971** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 53 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** IBI310
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT03545971
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-25
- **Primary completion:** 2021-09-10
- **Final completion:** 2022-08-09
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03545971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03545971, "A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03545971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*